INS and hyperinsulinism: The HOME (Hyperinsulinemia: the Outcome of its Metabolic Effects) trial found that the addition of metformin to insulin therapy reduced the risk of macrovascular disease (hazard ratio 0.61, 95% CI 0.40–0.94) [6].